1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legislation

Senate HELP Draft For Cosmetics Reform Does Not Go Far Enough – NGOs

 
• By Lauren Nardella

A coalition of businesses and advocacy groups including Breast Cancer Prevention Partners, Black Women for Wellness, and Women’s Voices for the Earth believes the Senate HELP Committee’s discussion draft for modernizing US cosmetics regulation should do more to protect communities of color and professional salon workers, and preemption language should be nixed altogether.

The Campaign for Safe Cosmetics and other NGOs are calling for revisions to a US Senate proposal for modernizing cosmetics regulation in the US, urging lawmakers to focus on strengthening safety standards and modifying preemption provisions.

The US Senate Health, Education, Labor and Pensions Committee released discussion draft legislation to reauthorize drug and medical device user...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 
• By Malcolm Spicer

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

More from Policy & Regulation

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 
• By Sarah Karlin-Smith

FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.

US FDA: No Replacement Yet For Animal Methods In Testing Systemic Effects Of Sunscreens

 
• By Lauren Nardella

While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.